Head & Neck Cancer | Topics

 
Lifileucel Plus Pembrolizumab Yields Positive ORR in Advanced Cancers
November 16, 2021

Patients with melanoma, head and neck squamous cell carcinoma, and cervical cancer who had not previously received immunotherapy and were treated with lifileucel plus pembrolizumab experienced promising overall response rates compared favorably with historical data on pembrolizumab monotherapy.

Experts Examine Tipifarnib to Treat HNSCC With HRAS Mutations
November 15, 2021

Cesar A. Perez, MD, and Victoria M. Villaflor, MD, discuss tipifarnib in patients with head and neck cancers harboring HRAS mutations.

HNSCC: Integrating Tipifarnib Into Treatment Algorithms
November 12, 2021

Potential implications of ongoing studies evaluating tipifarnib for patients with HRAS-mutated head and neck squamous cell carcinoma.

Individuals With HPV-Positive Oropharynx Cancer Likely to Have Pathologic ENE, Positive Margins Following TORS
November 09, 2021

Patients who received transoral robotic surgery for human papillomavirus–positive oropharynx squamous cell carcinoma were likely to experience pathologic extra nodal extension and positive margins following surgery.

Andrew Cook, MD, Discussed Exciting Clinical Trials Utilizing DART and Treatment De-Escalation in HPV+ OSCC
November 07, 2021

CancerNetwork® sat down with Andrew Cook, MD, at the 2021 American Society for Radiation Oncology to talk about exciting trials in the head and neck space, including the phase 2 ORATER2 and phase 3 MC1675 trials.

Andrew Cook, MD, on On-Going Clinical Research Efforts in the Head and Neck Cancer Space
November 06, 2021

CancerNetwork® sat down with Andrew Cook, MD, at the 2021 American Society for Radiation Oncology to discuss ongoing trials on treatment de-escalation and mitigating mucositis-related pain in head and neck cancer.

Tipifarnib in mHRAS HNSCC: Remaining Questions
November 05, 2021

Drs Cesar Perez and Victoria Meucci Villaflor consider questions raised by a recent study of tipifarnib in head and neck squamous cell carcinoma.

Andrew Cook, MD, on the Potential Role of Gabapentin in Head and Neck Cancer
November 05, 2021

CancerNetwork® sat down with Andrew Cook, MD, at the 2021 American Society for Radiation Oncology to discuss the potential role of gabapentin in head and neck cancer despite garnering negative results in oropharynx cancer.

Andrew Cook, MD, Discussed Outcomes with Gabapentin vs Opioids to Prevent Treatment-Related Pain in Oropharyngeal Cancer
November 04, 2021

CancerNetwork® sat down with Andrew Cook, MD, at the 2021 American Society for Radiation Oncology to discuss outcomes with gabapentin compared with opioids for increasing quality of life and decreasing treatment-related pain in oropharyngeal cancer.

Andrew Cook, MD, Discussed the Rational for Using Gabapentin to Prevent CRT-Related Pain in Oropharyngeal Cancer
November 03, 2021

CancerNetwork® sat down with Andrew Cook, MD, at the 2021 American Society for Radiation Oncology to talk about using prophylactic gabapentin for those receiving chemoradiotherapy for oropharyngeal cancer.